Dr. Eric Jonasch, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 166
Licensed in Texas since 2002, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license L5394 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 166
- Services billed
- 334
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 161 | 82 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 65 |
| Established patient office or other outpatient visit, 20-29 minutes | 39 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 21 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | 13 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | 14 |
| New patient office or other outpatient visit, 15-29 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cabometyx (cabozantinib s-malate) | 81 |
| Lenvima (lenvatinib mesylate) | 61 |
| Welireg (belzutifan) | 44 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Houston, TX | 37 |
| Everolimus | 33 |
| Levothyroxine Sodium Other prescribers in Houston, TX | 19 |
| Pantoprazole Sodium Other prescribers in Houston, TX | 17 |
| Dexamethasone Other prescribers in Houston, TX | 15 |
| Eliquis (apixaban) Other prescribers in Houston, TX | 15 |
| Ondansetron Odt (ondansetron) Other prescribers in Houston, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 98 payments worth $108,409 in total to this clinician.
| Merck Sharp & Dohme LLC | $54,188 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $36,934 |
| Eisai Inc. | $5,494 |
| Telix Pharmaceuticals | $3,159 |
| Eisai Co., LTD. | $2,910 |
| E.r. Squibb & Sons, L.l.c. | $2,434 |
| Orion Corporation | $1,500 |
| Exelixis Inc. | $770 |
| Travel and Lodging | $52,882 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $37,398 |
| Consulting Fee | $15,215 |
| Food and Beverage | $2,897 |
| Entertainment | $16.68 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $20,000 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 16, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $14,648 |
| Merck Sharp & Dohme LLC Dec 5, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $12,742 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging travel to Buenos Aires, Argentina · in-kind | $10,535 |
| Merck Sharp & Dohme LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $9,600 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $7,183 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,000 |
| Eisai Co., LTD. Sep 19, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| Eisai Inc. Sep 19, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| Eisai Inc. Mar 12, 2025 | Consulting Fee Lenvima · Oncology | $2,370 |
All 42 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 7, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $354 |
| Merck Sharp & Dohme LLC Dec 6, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $354 |
| Merck Sharp & Dohme LLC Dec 6, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $153 |
| Merck Sharp & Dohme LLC Dec 6, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind | $146 |
| Merck Sharp & Dohme LLC Dec 5, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $12,742 |
| Merck Sharp & Dohme LLC Dec 5, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $354 |
| Merck Sharp & Dohme LLC Dec 5, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $153 |
| Merck Sharp & Dohme LLC Dec 4, 2025 | Travel and Lodging travel to Singapore, Singapore · in-kind | $354 |
| E.r. Squibb & Sons, L.l.c. Nov 10, 2025 | Travel and Lodging travel to BOSTON, MA | $105 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $500 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Travel and Lodging travel to Berlin, Germany | $150 |
| Aveo Pharmaceuticals, Inc. Oct 20, 2025 | Entertainment FOTIVDA · Oncology · in-kind | $16.68 |
| Eisai Co., LTD. Sep 19, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| Eisai Inc. Sep 19, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,000 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Travel and Lodging travel to Frankfurt, Germany | $150 |
| Merck Sharp & Dohme LLC Sep 13, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $184 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $184 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $165 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $7,183 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Frankfurt, Germany · in-kind | $184 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $839 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $20,000 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 16, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $14,648 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 16, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $2,135 |
| Merck Sharp & Dohme LLC May 26, 2025 | Consulting Fee | $1,920 |
| Telix Pharmaceuticals May 22, 2025 | Consulting Fee | $1,035 |
| Telix Pharmaceuticals May 22, 2025 | Consulting Fee | $690 |
| Orion Corporation May 9, 2025 | Consulting Fee | $1,500 |
| Merck Sharp & Dohme LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $9,600 |
| Merck Sharp & Dohme LLC May 5, 2025 | Travel and Lodging travel to Buenos Aires, Argentina | $150 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging travel to Buenos Aires, Argentina · in-kind | $10,535 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging travel to Buenos Aires, Argentina · in-kind | $303 |
| Merck Sharp & Dohme LLC Apr 22, 2025 | Travel and Lodging travel to Buenos Aires, Argentina · in-kind | $441 |
| Merck Sharp & Dohme LLC Apr 22, 2025 | Travel and Lodging travel to Buenos Aires, Argentina · in-kind | $229 |
| Telix Pharmaceuticals Apr 17, 2025 | Consulting Fee | $1,380 |
| Ipsen Pharma Sas Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $653 |
| Eisai Inc. Mar 12, 2025 | Consulting Fee Lenvima · Oncology | $2,370 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $2,176,457 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Merck Sharp & Dohme LLC - STUDY NAME#Belzutifan's Role in Active surveillance Versus treatment for indolent metastatic clear cell Renal Cell Carcinoma BRAVE-RCC
Merck Sharp & Dohme LLC - A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors
Merck Sharp & Dohme LLC - Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
AbbVie Inc. · Recruiting · NCT04777994 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
AbbVie Inc. - STUDY NAME# Non-interventional post-authorization study of belzutifan in adult patients with von Hippel-Lindau disease-associated renal cell carcinoma, pancreatic neuroendocrine tumor and,or central nervous system hem…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.